Auristatin F is an MMAF analogused as a cytotoxin in ADC (Antibody-drug conjugates) synthesis, acting as highly potent antimitotic agent/tubulin inhibitor and anticancer agent that inhibits tubulin polymerization.

Mertansine refers to the thiol-containing maytansinoid, DM1 (N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) attached to a monoclonal antibody through reaction of the thiol group with an SPP (N-succinimidyl 4-(2-pyridyldithio)) linker to create an antibody-drug conjugate or ADC. Experimental ADCs with the SPP-DM1 design include lorvotuzumab mertansine. DM1 can also be linked to an antibody using the SMCC (4-(3-mercapto-2,5-dioxo-1-pyrrolidinylmethyl)-cylohexanecarboxylic acid) linker, […]

Maytansinoid DM4, a naturally occuring maytansine analogue, is a highly potent/cytotoxic antitubulin agent with anticancer properties. Maytansinoids have been shown to be able to disrupt microtubule function. Maytansinoid DM4 can be used for the preparation of antibody drug conjugates such as Anetumab ravtansine (BAY 94-9343) and Indatuximab ravtansine (BT062).

MMAF-OMe (Monomethyl auristatin F methyl ester-O-methyl), an auristatin-derived anticancer agent, is a novel and potent warhead used in ADC (antibody-drug conjugate). It acts as an inhibitor of tubulin polymerization.

N-Me-L-Ala-maytansinol is a maytansine derivative used as the warhead for antibody-drug conjugate (ADC).

PNU-159682 (PNU) is a highly potent metabolite of the anthracycline nemorubicin (MMDX) with excellent cytotoxicity. PNU-159682 was remarkably more cytotoxic than MMDX and doxorubicin in vitro, and was effective in the two in vivo tumor models tested, i.e., disseminated murine L1210 leukemia and MX-1 human mammary carcinoma xenografts.

TST-A , also known as Thailanstatin A, is a potent antiproliferative agent, which was isolated from the fermentation broth of B. thailandensis MSMB43